Pfizer Battles 2nd FCA Suit Over Antifungal Drug Promotions
Paul Worsfold, a former district manager at Pfizer, says his ex-employer recklessly and unnecessarily endangered patient health by encouraging unapproved uses of Vfend and Eraxis.
Alleged offenses include promoting off-label treatment in children under 12 and in individuals with neutropenia, a blood disorder commonly caused by cancer...
Already a subscriber? Click here to login